Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer-Reference-Cited by-同舟云学术

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Published:2018-08 Issue:8 Volume:29 Page:1701-1709
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bonomi P.D.,Gandara D.,Hirsch F.R.,Kerr K.M.,Obasaju C.,Paz-Ares L.,Bellomo C.,Bradley J.D.,Bunn Jr P.A.,Culligan M.,Jett J.R.,Kim E.S.,Langer C.J.,Natale R.B.,Novello S.,Pérol M.,Ramalingam S.S.,Reck M.,Reynolds C.H.,Smit E.F.,Socinski M.A.,Spigel D.R.,Vansteenkiste J.F.^ORCID,Wakelee H.,Thatcher N.

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/8/1701/25696276/mdy196.pdf

Reference61 articles.

1. Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004–2009;Houston;Lung Cancer,2014

2. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Reck;Ann Oncol,2014

3. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines®). Non-small cell lung cancer. Version 8.2017, July 2017. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (4 August 2017, date last accessed).

4. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

5. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer;Johnson;J Clin Oncol,2004

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lung Cancer: New Directions in Senior Patients Assessment;Geriatrics;2024-08-01

2. The promise and challenges of genomics‐informed periodontal disease diagnoses;Periodontology 2000;2024-06

3. Moving from conventional to adaptive risk stratification for oropharyngeal cancer;Frontiers in Oncology;2024-03-14

4. Anti-tumor Efficacy and Potential Mechanism of Pyrotinib in Locally Advanced Oral Squamous Cell Carcinoma;2023-10-17

5. LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway;Medical Oncology;2023-07-31